Stocks
Fate Therapeutics (FATE) EBITDA margin US GAAP (year values) |
|||||||||
| 2021 | 2022 | 2023 | 2024 | 2025 | LTM ? | CAGR 5 years ? | |||
| EBITDA margin, % | ? | -378.1% | -305.9% | -271.1% | -1 295% | -1 911% | -1 925% | ||
| Changes by years, y/y, % | +20pp | +72pp | +35pp | -1 024pp | -616pp | +36.9% | |||
Fate Therapeutics. EBITDA margin, %
Fate Therapeutics. EBITDA margin, changes, pp
Fate Therapeutics (FATE) EBITDA margin US GAAP (quarter values) |
||||||||
| 2025Q1 | 2025Q2 | 2025Q3 | 2025Q4 | 2026Q1 | LTM ? | |||
| EBITDA margin, % | ? | -2 329% | -1 615% | -1 667% | -2 312% | -2 316% | -1 925% | |
| Changes by years, y/y, % | +73pp | -1 019pp | -113pp | -44pp | +14pp | |||
| Changes by quarters, q/q, % | -61pp | +715pp | -52pp | -645pp | -3pp | |||
